COVID-19 associated mucormycosis – An emerging threat

Chien Ming Chao, Chih Cheng Lai, Wen Liang Yu

Research output: Contribution to journalReview articlepeer-review

20 Citations (Scopus)


Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations.

Original languageEnglish
Pages (from-to)183-190
Number of pages8
JournalJournal of Microbiology, Immunology and Infection
Issue number2
Publication statusPublished - Apr 2022


  • Corticosteroid
  • COVID-19
  • Diabetes mellitus
  • Fungus
  • Mucormycosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • General Immunology and Microbiology
  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'COVID-19 associated mucormycosis – An emerging threat'. Together they form a unique fingerprint.

Cite this